557 related articles for article (PubMed ID: 16629855)
1. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.
Walldius G; Jungner I
J Intern Med; 2006 May; 259(5):493-519. PubMed ID: 16629855
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke.
Walldius G; Jungner I
Curr Opin Cardiol; 2007 Jul; 22(4):359-67. PubMed ID: 17556890
[TBL] [Abstract][Full Text] [Related]
3. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
Walldius G; Jungner I
Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
[TBL] [Abstract][Full Text] [Related]
4. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study.
Walldius G; Aastveit AH; Jungner I
J Intern Med; 2006 Mar; 259(3):259-66. PubMed ID: 16476103
[TBL] [Abstract][Full Text] [Related]
5. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.
Sniderman AD; Jungner I; Holme I; Aastveit A; Walldius G
J Intern Med; 2006 May; 259(5):455-61. PubMed ID: 16629851
[TBL] [Abstract][Full Text] [Related]
6. ApoB/ApoA-I ratio in young patients with ischemic cerebral stroke or peripheral arterial disease.
Sabino AP; De Oliveira Sousa M; Moreira Lima L; Dias Ribeiro D; Sant'Ana Dusse LM; Das Graças Carvalho M; Fernandes AP
Transl Res; 2008 Sep; 152(3):113-8. PubMed ID: 18774540
[TBL] [Abstract][Full Text] [Related]
7. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study.
Juonala M; Viikari JS; Kähönen M; Solakivi T; Helenius H; Jula A; Marniemi J; Taittonen L; Laitinen T; Nikkari T; Raitakari OT
J Am Coll Cardiol; 2008 Jul; 52(4):293-9. PubMed ID: 18634985
[TBL] [Abstract][Full Text] [Related]
8. Apolipoproteins A-I and B-markers in coronary risk evaluation.
Agoston-Coldea L; Zdrenghea D; Pop D; Crăciun A; Rusu ML; Mocan T
Rom J Intern Med; 2007; 45(3):251-8. PubMed ID: 18333357
[TBL] [Abstract][Full Text] [Related]
9. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
Andrikoula M; McDowell IF
Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
[TBL] [Abstract][Full Text] [Related]
10. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS).
Holme I; Aastveit AH; Jungner I; Walldius G
J Intern Med; 2008 Jul; 264(1):30-8. PubMed ID: 18298486
[TBL] [Abstract][Full Text] [Related]
11. [Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers].
Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Ramal A; Schulman C; Vanhaeverbeek M; Ducobu J; Wespes E
Prog Urol; 2008 Dec; 18(13):1087-91. PubMed ID: 19041816
[TBL] [Abstract][Full Text] [Related]
12. [Apolipoproteins are new and better risk indicators of myocardial infarction].
Walldius G; Jungner I
Lakartidningen; 2004 Mar; 101(13):1188-94. PubMed ID: 15101244
[TBL] [Abstract][Full Text] [Related]
13. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
14. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
[TBL] [Abstract][Full Text] [Related]
15. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS).
Holme I; Aastveit AH; Hammar N; Jungner I; Walldius G
J Intern Med; 2009 Feb; 265(2):275-87. PubMed ID: 19019184
[TBL] [Abstract][Full Text] [Related]
16. Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease.
Sniderman AD; Holme I; Aastveit A; Furberg C; Walldius G; Jungner I
Am J Cardiol; 2007 Jul; 100(2):217-21. PubMed ID: 17631073
[TBL] [Abstract][Full Text] [Related]
17. Apolipoproteins as markers and managers of coronary risk.
Chan DC; Watts GF
QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
[TBL] [Abstract][Full Text] [Related]
18. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
[TBL] [Abstract][Full Text] [Related]
19. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men.
Lind L; Vessby B; Sundström J
Arterioscler Thromb Vasc Biol; 2006 Feb; 26(2):406-10. PubMed ID: 16306426
[TBL] [Abstract][Full Text] [Related]
20. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
